Uncategorized

Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity – Investors | Eli Lilly and Company

Posted on Author Comments Off on Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity – Investors | Eli Lilly and Company

Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity  Investors | Eli Lilly and CompanyEli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study  CNBCVideo Study suggests Zepbound can help patients dealing with heart failure  ABC NewsLive news: Eli Lilly’s weight loss drug cuts the risk of heart failure in latest trial  Financial TimesEli Lilly’s tirzepatide cuts heart failure risks, company says  NBC News